Physician profile
Hem A Deodhar
NPI 1497723555
$1,246.05
in general payments reported to CMS, 2019-2025
12 companies · $359 in 2025
The $359 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $173 · 2021: $149 · 2022: $65.21 · 2023: $73.38 · 2024: $427 · 2025: $359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $859.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $859.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $462.14 | 2021-2025 | |
| Aurinia Pharma U.S., INC. | $301.37 | 2021-2024 | Lupkynis |
| Ardelyx, INC. | $116.85 | 2024 | Xphozah 30 Mg |
| Genentech USA, INC. | $107.80 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $74.95 | 2019-2025 | Jynarque |
| Vifor Pharma, INC. | $38.29 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.30 | 2025 | |
| Amgen INC. | $27.25 | 2025 | Tavneos |
| Travere Therapeutics, INC. | $26.59 | 2019-2025 | |
| Calliditas Therapeutics US INC. | $23.37 | 2025 | Tarpeyo |
| Becton, Dickinson and Company | $21.09 | 2025 | Glidepath |
| Astrazeneca Pharmaceuticals LP | $13.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hem Deodhar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.